Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA

Article ID	Journal	Published Year	Pages	File Type
8819892	Respiratory Medicine	2018	7 Pages	PDF

Abstract

Patients receiving UMEC/VI progressed to TT more slowly, and were at lower risk of progressing to TT, than patients receiving TIO.

Keywords

UMEC MAPD TiO Umeclidinium PDE-4 FDC Chronic disease score PDP SABA IRR PSM ICD-9-CM ICS Tiotropium Vilanterol LAMA long-acting muscarinic antagonist Long-acting β2-agonist Short-acting β2-agonist Emergency room Clinical Modification standard deviation Olodaterol Long-acting bronchodilators Chronic obstructive pulmonary disease COPD Fixed-dose combination Propensity score matching Combination therapy Triple therapy LABA International Classification of Disease confidence interval phosphodiesterase-4 hazard ratio incidence rate ratio Ninth Revision CdS Inhaled corticosteroids Inhaled corticosteroid

Related Topics

Health Sciences Medicine and Dentistry Pulmonary and Respiratory Medicine

Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA

Authors

Beth Hahn, Michael Hull, Cori Blauer-Peterson, Ami R. Buikema, Riju Ray, Richard H. Stanford,